Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Ipsen inks $1.7B deal to buy Kartos for potential Jakafi add-on
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
James Waldron
Jun 29, 2026 8:03am
Scancell bids for Nasdaq-listed Neuphoria to raise US profile
Jun 29, 2026 7:55am
Talawar heads to Nasdaq via SPAC deal to fund eczema bispecific
Jun 29, 2026 7:00am
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
Jun 22, 2026 7:59am
Biogen inks $1B RayThera buyout to bag immunology assets
Jun 18, 2026 4:10am
Biogen is remaking its pipeline with an ‘entrepreneurial spirit’
Jun 16, 2026 8:50am
